Last reviewed · How we verify

Seagen Inc. — Portfolio Competitive Intelligence Brief

Seagen Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 3 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Taxotere (docetaxel) Taxotere (docetaxel) phase 3 Taxane Microtubules Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Air Force Military Medical University, China · 1 shared drug class
  2. Akeso · 1 shared drug class
  3. Biotech Pharmaceutical Co., Ltd. · 1 shared drug class
  4. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
  5. Central European Society for Anticancer Drug Research · 1 shared drug class
  6. Centre Leon Berard · 1 shared drug class
  7. Chengdu Kanghong Biotech Co., Ltd. · 1 shared drug class
  8. AbbVie (prior sponsor, Abbott) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Seagen Inc.:

Cite this brief

Drug Landscape (2026). Seagen Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/seagen-inc. Accessed 2026-06-10.

Related